#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome Barth syndrome IPEX syndrome Cutaneous T-cell lymphoma stage I Acute myeloid leukaemia recurrent Hydrocephalus Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndrome Optic ischaemic neuropathy Renal cancer metastatic Cataract Ovarian epithelial cancer Langerhans cell sarcoma Deafness bilateral Skin cancer Parkinson's disease More trials…

    Learn about Rare Diseases

    Osteosarcoma metastatic – Trials in Disease Lymphangioma – Life with Disease Ocular melanoma – Diagnostics Lymphatic malformation – Diagnostics Hepatoblastoma – Basic Information Angelman’s syndrome Osteosarcoma Mucopolysaccharidosis II – Life with Disease Usher’s syndrome – Basic Information SAPHO syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Odm-212 Etelcalcetide Beclometasone Dipropionate Progesterone Ph. Eur. Tumor Necrosis Factor-Alpha Furosemide Tofacitinib Mercaptopurine Monohydrate Sulfasalazine Medi0618 Lenzumestrocel Ptc518 11902A GSKVX000000070965 MORPHINE ZODASIRAN Rly-4008 Chlorhexidine Gluconate Sodium Chloride Solution 0.9% Alanyl Glutamine More therapies…

    Learn about Your Condition

    Huntington's disease Acoustic neuroma Pituitary tumour benign Endometrial adenocarcinoma Bone marrow disorder Carotid artery occlusion Device related infection Infant sedation Dermatitis Neurotrophic keratopathy Anal fistula Aortic valve disease Neuroblastoma Kidney transplant rejection Hepatitis alcoholic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Szpital Wojewodzki W Opolu Sp. z o.o.

Szpital Wojewodzki W Opolu Sp. z o.o.

Ul. Katowicka 64, Opole, 45-061, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Daunorubicin Hydrochloride
    • Ziftomenib
    • Azacitidine
    Belgium Czechia France Germany Greece Hungary +4

  • Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Daunorubicin Hydrochloride
    • Idarubicin Hydrochloride
    • Revumenib
    Austria Belgium Czechia France Germany Greece +7

  • A Study Comparing DZD8586 to Other Treatments for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Idelalisib
    • [(2S,5S)-5-{4-AMINO-5-[4-(2,3-DIFLUOROPHENOXY)PHENYL]IMIDAZO[5,1-F][1,2,4]TRIAZIN-7-YL}OXAN-2-YL]METHANOL
    • Bendamustine Hydrochloride
    Italy Poland

  • Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia refractory
    • Diffuse large B-cell lymphoma recurrent
    Investigated Drugs:
    • BGB-16673
    • Zanubrutinib
    • Glofitamab
    Germany Italy Poland

  • Study on the Safety and Effectiveness of HDP-101 for Patients with Relapsed or Refractory Multiple Myeloma

    Recruiting

    2 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Hdp-101
    Germany Hungary Poland Romania Spain

  • Study of SP-420 for Patients with Transfusion-Dependent Alpha or Beta Thalassemia

    Recruiting

    2 1 1
    Investigated Drugs:
    • (S)-4,5-Dihydro-2-[2-Hydroxy-4-(3,6-Dioxaheptyloxy)Phenyl]-4-Methyl-4-Thiazolecarboxylic Acid
    Denmark Greece Italy Poland

  • Study of TL-895 and Navtemadlin for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • B-cell small lymphocytic lymphoma
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • 1-4-{[6-Amino-5-(4-Phenoxy-Phenyl)-Pyrimidin-4-Ylamino]-Methyl}-4-Fluoro-Piperidin-1-Yl)-Propenone
    Hungary Poland

  • Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Myelofibrosis
    • Primary myelofibrosis
    Investigated Drugs:
    • Danazol
    • Hydroxycarbamide
    • Navtemadlin
    Bulgaria Croatia Czechia France Germany Greece +7

  • Study of Mosunetuzumab and Polatuzumab Vedotin for Patients with Diffuse Large B-Cell Lymphoma After Initial Treatment or in Elderly/Unfit Untreated Patients

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Polatuzumab Vedotin
    • Mosunetuzumab
    • Tocilizumab
    Poland Spain

  • Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Epcoritamab
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    Austria Belgium Bulgaria Croatia Czechia Denmark +10
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!